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Abstract: A phenazine-1-carboxylic acid intermediate was synthesized from the reaction of aniline 
and 2-bromo-3-nitro-benzoic acid. It was then esterified and reacted with hydrazine hydrate to af-
ford phenazine-1-carboxylic hydrazine. Finally, 10 new hydrazone compounds 3a–3j were ob-
tained by the condensation reaction of phenazine-1-carboxylic acid hydrazide and the respective 
aldehyde-containing compound. The structures were characterized by 1H and 13C NMR spectros-
copy, MS and single crystal X-ray diffraction. The antitumor activity of the target compounds in 
vitro (HeLa and A549) was determined by thiazolyl blue tetrazolium bromide. The results showed 
that compound (E)-N′-(2-hydroxy-4-(2-(piperidine-1-yl) ethoxy) benzyl) phenazine-1-carbonyl 
hydrazide 3d exhibited good cytotoxic activity. 




Acylhydrazone is formed by the condensation of hydrazine and an aldehyde or 
ketone, containing both oxygen and nitrogen atoms that are involved in the formation of 
hydrogen bonds in living organisms and increase the affinity between receptors, thereby, 
inhibiting numerous physiological and chemical processes in vivo [1–5]. Acylhydrazone 
compounds are special in terms of both their structure and properties and have been the 
focus of considerable research by chemists. The -CONH-N=CH- group has a large con-
jugate system, exhibits favorable stability and coordination ability [6–8], and can readily 
form chelates with iron/ferrous ions in the body. By changing the form of iron in this 
way, it prevents the absorption and utilization of iron by cells, thereby changing the dis-
tribution of iron in the body. In other words, it can regulate the distribution and metab-
olism of iron in the body. In particular, it can reduce cancer cell and tumor tissue iron 
content or can reduce the effective use of iron by cancer cells. It has the ability to make 
cancer cells and tissues iron “hungry” and can affect the activity of enzymes containing 
iron. In this way, the cancer cells′ energy metabolism, DNA replication, and transcription 
as well as protein synthesis and folding can be retarded or inhibited. The importance is 
highlighted because the division and growth can lead to the death [9–13]. Therefore, 
many hydrazone compounds are potential anticancer drugs because of their good anti-
cancer activity [14]. 
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Phenazine-1-carboxylic acid (PCA) is an antibiotic that can be used to protect crops 
against a broad spectrum of soil-borne fungal pseudomonas spp. [15]. It is widely found 
in the metabolites of many microorganisms, such as streptomyces [16] and Pseudo-
monads [17]. PCA can be isolated from the fermentation broth of Pseudomonas M-18 
[18]. It was found to have antituberculous bacterial properties and can inhibit seaweed 
growth [19,20]. PCA was confirmed by the Chinese pesticide naming unit, named as 
Shenazinamycin, which is an antibiotic secreted by Pseudomonas fluoresceae through bio-
logical culture. It has the dual functions of a broad-spectrum of inhibition of plant path-
ogens and the promotion of plant growth [21]. Rewcastle et al. synthesized a series of 
PCA analogs on the basis of original natural products and developed lead compounds 
possessing antilung cancer [22] and leukemia [23] properties and is currently in Phase II 
clinical trials [24]. PCA and its analogs isolated from secondary metabolites of Strepto-
myces sp. IFM 11694 can overcome the resistance of human gastric adenocarcinoma cells 
to TRAIL, a tumor necrosis factor related apoptotic inducing ligand, showing good an-
titumor activity [25]. However, the synthesis and bioactivity of PCA based acylhydra-
zones have not yet been reported. Therefore, we first synthesized PCA by a chemical 
synthesis method and then synthesized 10 new hydrazone compounds 3a–3j (Scheme 1) 
based on PCA. We also investigated the antitumor activity of the target compounds in 
vitro. Chemical synthesis of phenazine natural products by means of structural modifi-
cation or new synthesis of phenazine products are also emerging. The antitumor activity 
and structure activity relationship are also attracting increasing attention, and the 
mechanism of action may be related to interfering with respiratory chain, inhibiting 
topoisomerase activity and DNA breaking [26,27]. 
 
Scheme 1. Synthetic route to the acylhydrazone compounds 3a–3j. 
2. Results and Discussion 
2.1. Synthesis and Crystal Structures of the Target Compounds 
Phenazine biosynthesis has attracted attention since its early studies in the second 
half of the 20th century [28]. Ever since the total synthesis of PCA was reported by Kogl 
and Postowsky [29] in 1930, new reactions and synthetic strategies have emerged over 
the following half century, and the yield and route have been continuously improved 
and optimized. The synthetic route to the target compounds 3a–3j is shown in Scheme 1, 
and the structure and yields are shown in Table 1. According to reference [30], PCA was 
synthesized without the need for column chromatography during the synthesis process. 
Instead, relatively pure PCA was obtained by recrystallization from acetonitrile and 
ethanol (1:1). Then, PCA was esterified in concentrated sulfuric acid, and reacted with 
hydrazine hydrate to form acylhydrazine. Finally, the acylhydrazine compounds were 
condensed with aldehyde-containing compounds to afford the target compounds 3a–3j. 
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chloroform to ethanol is 1:1. Heating with frequent agitation, boiling to effect solution, 
and then slowing evaporation at room temperature resulted in 9 sets of crystals suitable 
for X-ray diffraction. The single crystal X-ray diffraction was performed, and the crystal 
structures revealed that the aldehyde compounds had reacted successfully with the 
amino group of the hydrazide. In all crystal structures, the hydrogen on the amide ni-
trogen atom and the nitrogen atom on the phenazine ring formed intramolecular N-H...N 
hydrogen bonds. The aldehydes containing ortho hydroxyl groups reacted with acylhy-
drazine to afford acylhydrazone compounds. Hydrogen atoms of the ortho hydroxyl 
groups and the imine nitrogen atoms also formed O-H...N intramolecular hydrogen 
bonds; thus, both the hydroxyl and carbonyl groups are on the same side, but on the 
other side of the phenazine ring (See Figure 1 for an example of the crystal structure of 3b; 
hydrogen bond distances are shown in Table S4). 
 
Figure 1. Crystal structure of compound 3b (dotted line represents hydrogen bond). 
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Table 1. Structure, yield and crystal structures of compounds 3a–3j. 
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2.2. Anticancer Activity of 3a–3f in Hela and A549 Cell Lines 
In our study, results are compared with cisplatin (20 μmol/L). Hela and A549 cells 
were seeded onto 96-well plates at the proper density and treated with 3a–3j at final 
concentrations for 24 h; cell viability was analyzed via an MTT assay. There was a pool of 
three different sets of experiments, each repeated in triplicate. Statistical comparisons 
were conducted. The results are shown in Table 2. 
Table 2. Anti-tumor activities of compounds 3a–3j [IC50/(μmol/L)]. 
Compd. Hela 
Statistical Analysis (Compared 
with the Control Group) A549 
Statistical Analysis (Compared 
with the Control Group) 
3a >100  >100  
3b 26.6 ± 4.8 ** p < 0.01 22.4 ± 3.7 ** p < 0.01 
3c 34.4 ± 4.1 ** p < 0.01 24.7 ± 4.7 ** p < 0.01 
3d 5.5 ± 1.3 *** p < 0.001 2.8 ± 1.53 *** p < 0.001 
3e 36.3 ± 2.3 *** p < 0.001 30.5 ± 1.9 *** p < 0.001 
3f 32.8 ± 3.9 ** p < 0.01 28.6 ± 3.5 ** p < 0.01 
3g >100  >100  
3h >100  >100  
3i >100  >100  
3j >100  >100  
cisplatin 20.4 ± 4.8 ** p < 0.01 11.6 ± 2.25 *** p < 0.001 
** denotes significance (p < 0.01) vs. control, *** denotes significance difference (p < 0.001) vs. control. 
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The activity showed that the compounds 3b–3f were effective in the Hela and A549 
cell lines, among which 3d had the strongest effect on Hela and A549 cells. Compound 3d 
revealed better cytotoxic activity than cisplatin, with IC50 values of 5.5 ± 1.3 and 2.8 ± 1.53 
μmol/L against HeLa and A549, respectively, with statistical significance (*** p < 0.001, 
significantly different from the value of control group, n = 3).  
The antitumor activity of phenazine compounds has been widely studied, and can 
induce cell apoptosis and cycle arrest. The mechanism of action is related to the inhibition 
of topoisomerase and the induction of reactive oxygen species. DNA, which is regarded 
as an important genetic material of cell life, has become the target of many antitumor 
drugs. Phenazine compounds have planar macromolecular structures for intramolecular 
hydrogen bonding. The shorter the hydrogen bond distance, the more stable the struc-
ture. It may bind to DNA in a way similar to ethidium bromide and campinetin [31].  
According to previous reports, compounds that bear hydrazide-hydrazone moiety 
have received considerable attention due to their biological value in the development of 
novel antimicrobials and analgesic, anti-inflammatory, and anticancer agents [32]. The 
compound PAC-1 (Figure 2) was reported to enhance the activity of procaspase-3 in 
vitro and induce apoptosis in tumor cells in vivo [33]. The cells were treated with dif-
ferent concentrations (0, 0.1, 1, 10, 100, and 1000 μmol/L) of synthesized compounds. 
Picolinoylhydrazone derivative (1) (Figure 3) is a potent growth inhibitor of lung, leu-
kemia and ovarian cancer cell lines, with IC50 values below 10 μmol/L [34]. A bis-isatin 
hydrazones of imidazolidine-2, 4-dione (2) (Figure 4) showed good antiproliferative ac-

















Figure 3. The structure of 1. (IC50 = 8.07 μmol/L, A549; IC50 = 0.76 μmol/L, KG-1; IC50 = 0.18 
μmol/L, A2780). 
















Figure 4. The structure of 2. (IC50 = 23.73 μmol/L, HCT-116).  
A series of novel pyrano [3,2-a]phenazine derivatives (Figure 5), designed as hybrid 
molecules of phenazine and pyran pharmocophores and then treated with compounds 
at concentrations from 0 to 50 μmol/L. Cytotoxic evaluation indicates that many com-
pounds exhibited cytotoxicity against HCT116, MCF7, HepG2 and A549 cancer cell lines 
in vitro, in which compounds 1c, 1i, 2e, and 2l were found to have excellent antiprolifer-
ative activity against the HepG2 cancer cell line [35]. This provided the experimental ba-
sis for the further mechanism of 3a–3j and its influence on tumor cells. 
 
Figure 5. The structure of pyrano[3,2-a]phenazine derivatives. (1c: R1, R2, R4, R5 = H, R3 = Cl. 1i: R1, 
R4, R5 = H, R2, R3 = Cl. 2e: R1 = Br, R2, R3, R4, R5=H. 2l: R1, R2 = Cl, R3, R4, R5 = H). 
Compared with the above structures, 3a–3j all have a hydrazine structure and IC50 
values of 3d below 10 μmol/L. Significantly, 3d showed more potency than the positive 
control drug, which is a potent growth inhibitor of HeLa and A549 cells. It can be seen 
from Table 2 that the hydrazine obtained by the condensation reaction of phena-
zine-1-hydrazine with the salicylaldehyde and salicylaldehyde analogs have certain an-
titumor activity, while the hydrazine obtained by the condensation reaction of other al-
dehydes with phenazine-1-hydrazine has no activity. The specific antitumor activity 
mechanism, whether by inhibiting enzyme activity or not, needs further study. 
3. Materials and Methods 
3.1. Instruments and Reagents 
1H/13C NMR spectra were measured on a Inova-400-Bruker AV600 NMR spectrom-
eter, with d-DMSO as solvent and tetramethylsilane as internal reference (600 MHz), and 
the J value was in Hz. High resolution mass spectrometry (HRMS) was performed using 
a GCT premier CAB048 mass spectrometer. Data for the crystal structures were collected 
on a Bruker Smart Apex single crystal diffractometer. Melting points were measured on 
a Yanaco microscopic melting point meter, and the temperature was not corrected. Hela 
and A549 cells were replaced in a fresh culture medium and incubated for 24 h in a hu-
midified atmosphere of 95% air and 5% CO2 at 37 °C (Thermo-Fisher, New York, NY, 
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USA). MTT assay was analyzed by Epoch Continuous Wavelength Microplate (Bio-Tek, 
Burlington, VT, USA) and RPMI-1640 medium (Gibco, New York, NY, USA). Solvents 
and reagents were obtained commercially and were of analytical grade. 
3.2. Determination of the Crystal Structures of the Compounds 
The target compounds were dissolved in chloroform and slowly evaporated for 5–
10 days to obtain crystals of appropriate size. A Bruker Smart Apex CCD single crystal 
diffractometer and a graphite monochromator with monochromatized Mo Kα rays (λ = 
0.071073 nm) were used to collect single crystal diffraction data within a certain θ range 
by φ-ω scanning mode. The diffraction intensity data were corrected by empirical ab-
sorption and LP. The crystal structures were solved by direct methods. All 
non-hydrogen coordinates and their anisotropic thermal parameters were modified by 
the full matrix least square method. All calculations were completed with the Shelx-97 
program [36]. Crystallographic data and refinement details for 3a–3j are given in Tables 
S1–S3. CCDC: 2102942, 3a. CCDC: 2102943, 3b. CCDC: 2102944, 3c. CCDC: 2102945, 3e. 
CCDC: 2102946, 3f. CCDC: 2102947, 3g. CCDC: 2102948, 3h. CCDC: 2102949, 3i. CCDC: 
2102950, 3j. These data can be obtained free of charge from the Cambridge Crystallo-
graphic Data Centre www.ccdc.cam.ac.uk/data_request/cif (accessed on 13 August 
2021). 
3.3. Synthesis of Compounds 
3.3.1. Synthesis of PCA 
Aniline (2.5 g, 26.8 mmol), 2-bromo-3-nitrobenzoic acid (6.3 g, 26.6 mmol), CuI (1.3 
g, 6.8 mmol) and triethylamine (12.5 mL, 90.0 mmol) were weighed out and combined 
with glycol (50.0 mL, 899.1 mmol), dissolved in a 100 mL three-mouth flask and the sys-
tem heated at 95 °C for 3 h. On cooling to room temperature, it was poured into a 0.2 
mol/L sodium hydroxide (300 mL, 60 mmol) solution. Work-up included silica gel ad-
sorption decolorization and extraction and filtration to afford a red solution, which was 
then acidified with dilute hydrochloric acid to pH = 3, affording the product 
3-nitro-2-(phenylamino) benzoic acid. This product was pure enough to be directly used 
in the next reaction. 
The solution of 3-nitro-2-(phenylamino) benzoic acid (4.0 g, 15.5 mmol) and NaBH4 
(4.8 g, 126.0 mmol) was dissolved in 2 mol/L sodium hydroxide (450 mL, 900 mmol), re-
fluxed for 4 h, and then the sodium salt solution of phenazine carboxylic acid was ob-
tained after cooling. A green solid was obtained by adjusting the pH of the solution with 
dilute hydrochloric acid to pH = 3. The solid was recrystallized with a mixture of ace-
tonitrile and ethanol (1:1) to obtain yellow-green crystalline PCA. 
3.3.2. Synthesis of Phenazine-1-hydrazide 
Concentrated sulfuric acid (1 mL) was slowly added to 100 mL of anhydrous etha-
nol in an ice bath, restored to room temperature, and then PCA (2.24 g, 10 mmol) was 
added to the solution, which was refluxed for 21 h. Then the solution was cooled to 
room temperature. The concentrated solution was steamed to 50 mL, and the solution 
was poured into 200 mL of ice water. With saturated potash, the pH was adjusted to pH 
= 10, and then extraction with dichloromethane (60 mL × 4) was conducted. The organic 
phase was collected and combined, and then dried overnight with anhydrous sodium 
sulfate and filtered and rotary steamed to remove the dichloromethane to afford a black 
solution. Then, 40 mL anhydrous ethanol and 5 mL hydrazine hydrate were added to 
the black solution, and the system was refluxed for 8 h. After cooling, the solids were 
separated out and filtered, and phenazine-1-hydrazine was obtained after washing with 
anhydrous ethanol for three times and drying. 
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3.3.3. Synthesis of the Acylhydrazone Compounds 
Ten aldehydes were weighed out, and each was dissolved in 30 mL anhydrous 
ethanol with phenazine-1-hydrazine at a molar ratio of 1:1. Following refluxing for 8 h 
and upon cooling, a solid separated out, and filtration followed by ethanol washing for 3 
times to obtain a brown solid. The solid was recrystallized with chloroform and ethanol 
and filtered and dried to obtain the acylhydrazone compounds. 
(E)-N′-(isoquinoline-3-methyl)phenazine-1-carbonyl hydrazide (3a): brown solid 0.23 g, yield 
60%, m. p. 256–257 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.28 (s, 1H, NH), δ 8.72 
(s, 1H, isoquinoline-H), δ 8.60 (d, J = 6.0 Hz, 1H, quinoline-H), 8.53 (d, J = 12.0 Hz, 1H, 
isoquinoxaline-H), 8.5. (d, J = 6.0 Hz, 1H, quinoline-H), 8.48 (d, J = 6.0 Hz, 1H, isoquinox-
aline-H), 8.34 (t, J = 12.0 Hz, 1H, isoquinoline-H), 8.23 (s, 1H, N=CH), 8.14–8.08 (d, J = 6.0 
Hz, 2H, quinoline-H), 8.7–8.04 (m, 2H, quinoline-H), 7.92–7.82 (m, 2H, isoquinoline-H), 
7.68 (d, J = 12.0 Hz, 1H, isoquinoline-H). 13C NMR (150 MHz, d-DMSO): δC (ppm): 162.0, 
153.7, 148.4, 147.3, 142.8, 142.5, 141.6, 139.8, 136.7, 133.3, 132.8, 132.0, 131.8, 131.5, 130.3, 
130.0, 129.6, 129.1, 128.8, 128.0, 127.9, 127.3, 117.6. HRMS (ESI+) m/z Calcd for C23H15N5O 
[M + H]+ 378.1322, found: 378.1352. 
(E)-N′-(2-hydroxybenzyl)phenazine-1-carbonyl hydrazide (3b): brownish yellow powder 0.22 
g, yield 65%, m. p. 270–271 °C ; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.28 (s, 1H, 
NH), 11.36 (s, 1H, OH), 8.82 (s, 1H, N=CH), 8.63 (d, J = 6.0, 1H, quinoxaline-H), 8.57–8.47 
(d, J = 12.0 Hz, 2H, quinoxaline-H), 8.34 (d, J = 12.0 Hz, 1H, quinoxaline-H) 8.16–8.06 (m, 
3H, quinoxaline-H), 7.64 (d, J = 6.0 Hz, 1H, benzylidenimin-H), 7.36 (t, J = 6.0 Hz, 1H, 
benzylidenimin-H), 7.00 (d, J = 6.0 Hz, 1H, benzylidenimin-H), 6.99 (t, J = 6.0 Hz, 1H, 
benzylidenimin-H). 13C NMR (150 MHz, d-DMSO): δC (ppm): 161.3, 157.5, 149.3, 142.8, 
142.5, 141.5, 139.7, 133.6, 132.9, 132.0, 131.8, 131.5, 130.7, 130.3, 129.8, 129.4, 129.2, 119.3, 
118.5, 116.4. HRMS (ESI+) m/z Calcd for C20H14N4O2 [M + H]+ 343.1211, found: 343.1195. 
(E)-N′-(3,5-dibromo-2-hydroxybenzy)phenazine-1-carbonyl hydrazide (3c): yellow powder 
0.32 g, yield 65%, m. p. 269–270 °C ; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.70 (s, 1H, 
NH), 12.64 (s, 1H, OH), 8.80 (s, 1H, N=CH), 8.67 (d, J = 6.0 Hz, 1H, quinoxaline-H), 8.54 
(d, J = 12.0 Hz, 2H, quinoxaline-H), 8.36 (d, J = 6.0 Hz, 1H, quinoxaline-H), 8.18–8.06 (m, 
3H, quinoxaline-H), 7.88 (s, 2H, benzylidenimin-H). Due to the poor solubility of com-
pound 3c, we could not obtain 13C-spectral data, HRMS (ESI+) m/z Calcd for 
C20H12Br2N4O2 [M + H]+ 498.9310, found: 498.9400. 
(E)-N′-(2-hydroxy-4-(2-(piperidine-1-yl)ethoxy)benzyl) phenazine-1-carbonyl hydrazide (3d): 
orange yellow powder 0.26 g, yield was 55%, m. p. 203–204 °C; 1H NMR (600 MHz, 
d-DMSO): δH (ppm): 13.24 (s, 1H, NH), 11.66 (s, 1H, OH), 8.73 (s, 1H, N=CH), 8.63 (d, J = 
6.0 Hz, 1H, quinoxaline-H), 8.55–8.45 (d, J = 6.0 Hz, 2H, quinoxaline-CH), 8.34 (d, J = 6.0 
Hz, 1H, quinoxaline-H), 8.18–7.92 (m, 3H, quinoxaline-H), 7.50 (s, 1H, benzyli-
denimin-H), 6.58 (s, 1H, benzylidenimin-H), 6.54 (d, J = 6.0 Hz, 1H, benzylidenimin-H), 
4.12–2.62 (t, J = 6.0 Hz, 4H, methylene-H), 2,48–1.39 (m, 10H, piperidine-H). 13C NMR 
(150 MHz, d-DMSO): δC (ppm): 161.4, 160.8, 159.5, 149.8, 142.7, 142.6, 141.4, 139.7, 133.6, 
132.9, 132.0, 131.8, 131.4, 130.5, 130.3, 129.4, 129.1, 111.5, 107.6, 106.9, 101.6, 101.2, 65.7, 
57.2, 54.3, 25.5, 223.8. HR-MS (ESI+) m/z Calcd for C27H27N5O3 [M]+ 470.2102, found: 
470.2194. 
(E)-N′-(2-hydroxy-3-methoxybenzyl)phenazine-1-carbonyl hydrazide (3e): brown solid 0.25 g, 
yield 68%, m. p. 190–191 °C; 1H NMR(600 MHz, d-DMSO): δH (ppm): 13.24 (s, 1H, OH), 
11.10 (s, 1H, NH), 8.81 (s, 1H, N=CH), 8.63–8.26 (d, J = 12.0 Hz, 4H, quinoxaline-H), 8.19–
7.92 (m, 3H, quinoxaline-H), 7.25–7.08 (d, J = 12.0 Hz, 2H, benzylidenimin-H), 6.92 (t, J = 
12.0 Hz, 1H, benzylidenimin-CH), 3.85 (s, 3H, OCH3). 13C NMR (150 MHz, CHCl₃): δC 
(ppm): 161.2, 149.1, 147.8, 147.2, 142.7, 142.5, 141.4, 139.7, 133.6, 132.9, 132.0, 131.7, 130.6, 
129.4, 129.1, 121.1, 118.9, 118.6, 113.9, 79.0, 55.7. HRMS (ESI+) m/z Calcd for C21H16N4O3 
[M + H]+ 373.1102, found: 373.1298. 
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(E)-N′-(2,4-dihydroxybenzyl)phenazine-1-carbon hydrazide (3f): yellow-brown powder 0.25 
g, the yield of 70%, m. p. 297–298 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.18 (s, 
1H, OH), 11.54 (s, 1H, OH), 10.04 (s, 1H, NH), 8.67 (s, 1H, N=CH), 8.61 (d, J = 6.0 Hz, 1H, 
quinoxaline-H), 8.50-8.27 (d, J = 12.0 Hz, 3H, quinoxaline-H), 8.09-8.02 (m, 3H, quinoxa-
line-H), 7.40 (d, J = 6.0 Hz, 1H, benzylidenimin-H), 6.42 (s, 1H, benzylidenimin-H), 6.37 
(d, J = 6 Hz, 1H, benzylidenimin-H). 13C NMR (150 MHz, d-DMSO): δC (ppm):160.8, 
160.6, 159.6, 150.1, 142.7, 142.5, 141.2, 139.6, 133.7, 132.9, 132.0, 131.7, 131.7, 130.3, 130.3, 
129.3, 129.1, 110.4, 107.7, 102.6. HRMS (ESI+) m/z Calcd for C20H14N4O3 [M + H]+ 359.1102, 
found: 359.1140. 
(E)-N′-(pyridine-2-methyl)phenazine-1-carbonyl hydrazide (3g): reddish-brown crystalline 
0.20 g, yield 60%, m. p. 220–221 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.10 (s, 1H, 
NH), 8.67 (d, J = 6.0 Hz, 1H, 2-pyridine-H), 8.56–8.49 (d, J = 6.0 Hz, 2H, quinoxaline-H), 
8.48 (s, 1H, N=CH), 8.33 (t, J = 12.0 Hz, 1H, quinoxaline-H), 8.12 (d, J = 6.0 Hz, 1H, 
2-pyridine-H), 8.07 (t, J = 6.0 Hz, 1H, quinoxaline-H), 8.06–8.02 (m, 2H, quinoxaline-H), 
7.95 (t, J = 12.0 Hz, 2H, 2-pyridine-H ), 7.47 (s, 1H, N=CH). 13C NMR (150 MHz, 
d-DMSO): δC (ppm): 161.9, 153.1, 149.5, 148.4, 142.8, 142.5, 141.6, 139.8, 136.8, 133.0, 132.7, 
132.0, 131.8, 131.7, 130.3, 129.5, 129.1, 124.5, 120.7. HRMS (ESI+) m/z Calcd for C19H13N5O 
[M + H]+ 328.1102, found: 328.1196. 
(E)-N′-(pyridine-3-methyl)phenazine-1-carbonyl hydrazide (3h): yellowish brown crystal 0.20 
g, yield 60%, m. p. 230–231 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.37 (s, 1H, 
NH), 8.97 (s, 1H, 3-pyridine-H), 8.67 (s, 1H, N=CH), 8.64 (d, J = 6.0 Hz, 1H, 
3-pyridine-H), 8.53 (d, J = 6.0 Hz, 1H, 3-pyridine-H), 8.48 (d, J = 6.0 Hz, 1H, quinoxa-
line-H) 8.34–8.24 (d, J = 6.0 Hz, 2H, quinoxaline-H), 8.11 (d, J = 6.0 Hz, 1H, 3-pyridine-H), 
8.11–8.03 (m, 3H, quinoxaline-H), 7.55 (t, J = 6.0 Hz, 1H, 3-pyridine-H). 13C NMR (150 
MHz, d-DMSO): δC (ppm): 161,4, 150.7, 148.8, 145.8, 142.7, 142.6, 141.3, 139.7, 133.7, 133.5, 
133.0, 132.0, 131.8, 130.7, 130.3, 130.2, 129.4, 129.2, 124.0. HRMS (ESI+) m/z Calcd for 
C19H13N5O [M + H]+ 328.1102, found: 328.1200. 
(E)-N′-(pyridine-4-methyl)phenazine-1-carbonyl hydrazide (3i): yellow powder 0.20 g, yield 
60%, m. p. 243–244 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 13.42 (s, 1H, NH), 8.72 
(d, J = 6.0 Hz, 2H, 4-pyridine-H), 8.62 (s, 1H, N=CH), 8.57–8.47 (d, J = 6.0 Hz, 2H, quinox-
aline-H), 8.37–8.32 (d, 2H, quinoxaline-H), 8.14–8.05 (m, 3H, quinoxaline-H), 7.78 (d, J = 
6.0 Hz, 2H, 4-pyridine-H). 13 C NMR (150 MHz, CHCl₃): δC (ppm): 161.3, 151.1, 148.5, 
143.4, 141.0, 140.2, 136.6, 134.6, 132.3, 131.4, 130.2, 130.0, 128.6, 127.8, 122.6, 119.0, 118.0, 
114.1, 56.3. HRMS (ESI+) m/z Calcd for C19H13N5O [M + H]+ 328.1102, found: 328.1198. 
(E)-N′-((2-hydroxynaphthalene-1-yl)methyl)phenazine-1-carbonyl hydrazide (3j): orange 
powder 0.24 g, yield 62%, m. p. 276–277 °C; 1H NMR (600 MHz, d-DMSO): δH (ppm): 
13.45 (s, 1H, OH), 13.01 (s, 1H, NH), 9.67 (s, 1H, N=CH), 8.72 (d, J = 6.0 Hz, 1H, quinoxa-
line-H), 8.69 (d, J = 6.0 Hz, 1H, 1-naphthalene-H), 8.52–8.32 (d, J = 12 Hz, 3H, quinoxa-
line-H), 8.16–8.09 (m, 3H, quinoxaline-H), 7.98–7.91 (d, J = 12.0 Hz, 2H, 
1-naphthalene-H), 7.65–7.43 (t, J = 6.0 Hz, 2H, 1-naphthalene-H), 7.28 (d, J = 6.0 Hz, 
1-naphthalene-H). 13C NMR (150 MHz, d-DMSO): δC (ppm): 161.0, 158.2, 147.7, 142.6, 
141.4, 139.7, 134.1, 133.3, 132.8, 132.1, 131.8, 131.7, 130.3, 130.0, 129.8, 129.1, 128.8, 127.7, 
127.6, 123.5, 121.2, 118.9, 108.6,79.1. HRMS (ESI+) m/z Calcd for C24H16N4O2 [M + H]+ 
393.1112, found: 393.1350. 
3.4. Antitumor Activity Assays 
Using cisplatin as a positive control, the in vitro antitumor activity of the target 
compounds was determined by MTT assays [8]. A549 cells were cultured in RPMI 1640 
medium at 37 °C with 5% CO2 and 95% air, supplemented with 10% (v/v) bovine calf 
serum and 80 μg/mL gentamicin. Hela cells were cultured in DMEM (high glucose) me-
dium under the same condition as above. The logarithmic growth phase cells were inoc-
ulated in a 96-well culture plate at a concentration containing the medium at the cell 
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density is 5 × 103 cells per well. After 24 h of culture, the cells were attached to the well, 
and the old culture medium was discarded. The compounds to be tested were dissolved 
in DMSO, and the final concentration was diluted in the culture medium. The complete 
culture medium containing different concentrations of compounds were replaced, six 
concentration gradients were set (2.5 to 100 μmol/L). Each concentration had 3 complex 
holes, the zeroing group containing only the culture medium. After treatment for 48 h, 
20 μL MTT (5 mg/mL) was added to each well, and the culture was continued for 4 h. 
The medium was centrifuged at 3000 rpm for 10 min, and 150 μL DMSO was added. The 
absorbance was measured at 570 nm by a microplate analyzer, and the IC50 value was 
calculated. 
3.5. Statistical Analysis 
Data were presented as from at least three independent experiments. Results were 
reported as mean ± SD and analyzed by Student’s t test. Results were considered signif-
icant when a p value < 0.05 was obtained. 
4. Conclusions 
PCA intermediates were synthesized from aniline and 2-bromo-3-nitrobenzoic acid. 
Then, PCA was esterified, and acylhydrazide was synthesized. Finally, 10 new hydra-
zine-1-carboxylic acid compounds containing aldehyde groups were obtained by the 
condensation reaction of PCA with hydrazine-containing compounds. Their structures 
were characterized by 1H and 13C NMR spectroscopy, MS and single crystal X-ray dif-
fraction. The in vitro antitumor activity of the target compounds (HeLa and A549) was 
tested by MTT assays. The results showed that the compounds exhibited good cytotoxic 
activity, particularly 3d, which has potential to be used for further studies. 
Supplementary Materials: The following are available online: Figures S1–S10: 1H NMR of com-
pound 3a to 3j. Figure S11–S19: 13C NMR of compound 3a to 3j. Figures S20–S29: HRMS of com-
pound 3a to 3j. Table S1: Crystal data and structure refinement for the compound 3a–3c. Table S2: 
Crystal data and structure refinement for the compound 3e–3g. Table S3: Crystal data and struc-
ture refinement for the compound 3h–3k. Table S4: Hydrogen bond parameters [Å and °] in the 
crystal structure of compounds 3a–3j. 
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